Cargando…
Optimal pathological response indicated better long-term outcome among patients with stage IB2 to IIB cervical cancer submitted to neoadjuvant chemotherapy
The role of pathological response in long-term outcome is still unclear in cervical cancer patients treated with neoadjuvant chemotherapy (NACT) in China. This study aimed to investigate the effect of optimal pathologic response (OPR) on survival in the patients treated with NACT and radical hystere...
Autores principales: | Huang, Kecheng, Sun, Haiying, Chen, Zhilan, Li, Xiong, Wang, ShaoShuai, Zhao, Xiaolin, Tang, Fangxu, Jia, Yao, Hu, Ting, Du, Xiaofang, Wang, Haoran, Lu, Zhiyong, Huang, Jia, Gui, Juan, Wang, Xiaoli, Zhou, Shasha, Wang, Lin, Zhang, Jincheng, Guo, Lili, Yang, Ru, Shen, Jian, Zhang, Qinghua, Li, Shuang, Wang, Shixuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915007/ https://www.ncbi.nlm.nih.gov/pubmed/27325186 http://dx.doi.org/10.1038/srep28278 |
Ejemplares similares
-
Prognostic risk model development and prospective validation among patients with cervical cancer stage IB2 to IIB submitted to neoadjuvant chemotherapy
por: Huang, Kecheng, et al.
Publicado: (2016) -
Risk model in stage IB1-IIB cervical cancer with positive node after radical hysterectomy
por: Chen, Zhilan, et al.
Publicado: (2016) -
Adjuvant chemotherapy after surgery can improve clinical outcomes for patients with IB2-IIB cervical cancer with neoadjuvant chemotherapy followed by radical surgery
por: Sun, Haiying, et al.
Publicado: (2018) -
The Predictive Value of Serum Squamous Cell Carcinoma Antigen in Patients with Cervical Cancer Who Receive Neoadjuvant Chemotherapy followed by Radical Surgery: A Single-Institute Study
por: Li, Xiong, et al.
Publicado: (2015) -
A Fifteen‐Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer
por: Tian, Xun, et al.
Publicado: (2021)